![[CME 1] Mastering Major Depressive Disorder Psychopharmacology](https://psychiatryeducationforum.com/wp-content/uploads/2020/11/Untitled-design-2.png)
CME ACADEMY #1
MASTERING
MAJOR DEPRESSIVE DISORDER
PSYCHOPHARMACOLOGY
TOTAL CREDITS: 8.50 AMA PRA CATEGORY 1 CREDITS
ENROLLEMENT CLOSED
LEARNING OBJECTIVES:
- Evaluate the pharmacological mechanisms and clinical efficacy of various antidepressants used in treating Major Depressive Disorder (MDD).
- Apply evidence-based strategies to optimize antidepressant selection and dosing, tailored to individual patient profiles.
- Integrate adjunctive treatment options to enhance therapeutic outcomes in patients with treatment-resistant depression.
- Differentiate between various antidepressants in terms of their pharmacokinetics, efficacy, and side effect profiles.
Course Instructor
TABLE OF CONTENT:
Foundations and Treatment Strategies
Efficacy and Special Considerations
Integrative and Alternative Approaches
Comparative Analysis of Antidepressants
Earn CME Certificate
ENROLLEMENT CLOSED
Accreditation and Designation Statements and Disclosure Report:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the Psychiatry Education Forum.
PeerPoint Medical Education Institute designates the live format for this educational activity for a maximum of 8.50 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- Enduring activity date: September 1, 2024 – September 1, 2025
Financial Disclosures:
- All presenters, planners, editors, or staff report no relationships to disclose: “I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies.”
